Pfizer Inc. shares saw a modest uptick on Tuesday, closing at $26.04, up 0.15%, following the announcement that Rigel Pharmaceuticals has finalized a licensing agreement for the breast cancer drug Veppanu, developed in collaboration with Arvinas and Pfizer. The deal includes a $70 million upfront payment, which will be split equally between Arvinas and Pfizer, resulting in a $35 million payment to Pfizer.
Market Context
The broader U.S. stock market finished mixed, with the S&P 500 slipping 0.57% and the Nasdaq losing 1.15%, while the Dow Jones Industrial Average gained 0.64% to reach a record close, as investors rotated out of technology stocks into other sectors. Pfizer's slight gain came amid this mixed trading environment, offering a small positive note for the pharmaceutical giant.
Deal Details
Rigel announced that the Veppanu licensing deal took effect on June 11, following antitrust clearance and other necessary approvals. The company paid the $70 million upfront in cash at closing. Rigel expects Veppanu to hit the market in August. Veppanu is approved in the U.S. for treating adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer after disease progression on at least one line of endocrine therapy. The drug is used when hormone-based treatments fail and the patient's ESR1 gene has mutated.
Investor Sentiment
Despite the positive news, Pfizer's stock remains under pressure as investors continue to evaluate whether the company's oncology and obesity pipeline can offset declining COVID-19 product sales and looming patent expirations. The drugmaker is working to demonstrate that a combination of new drugs, recent acquisitions, and late-stage pipeline bets can drive future growth. However, the urgency from COVID-19 has faded, and several older drugs are nearing loss of exclusivity, which will bring generic competition.
Analysts are divided on Pfizer's prospects. RBC Capital's Trung Huynh recently upgraded the stock to Sector Perform from Underperform, citing a more balanced risk-reward profile, but left his price target at $25. He is looking to two major clinical updates coming in 2026. J.P. Morgan's Chris Schott noted that pipeline drugs could make the story more interesting over time, but sentiment is unlikely to improve without more data and reduced risk.
Pipeline Focus
Pfizer is directing investor attention to its obesity efforts, as rivals Eli Lilly and Novo Nordisk currently dominate the field. The company recently announced Phase 2b results supporting the advancement of berobenatide, a GLP-1 receptor agonist, into Phase 3 obesity studies. The drug mimics a hormone used in diabetes and obesity treatments. Jim List at Pfizer stated that the drug showed continuous, uninterrupted weight loss in selected studies heading into Phase 3.
Pfizer's core business continues to rely on a broad portfolio of drugs, including the blood thinner Eliquis, which it markets with Bristol Myers Squibb. The company reported first-quarter revenue of $14.5 billion, up 2% on an operational basis, with sales of launched and acquired products rising 22%. CFO David Denton reaffirmed the company's full-year 2026 guidance.
Analyst Consensus
MarketScreener lists 29 analysts covering Pfizer, with an average rating of Outperform and a price target of $29.19, representing about 12% upside from the last close. Price targets range from $24 to $36, reflecting the trade-off between income and potential pipeline upside versus slow growth and patent headwinds.
Risks
Rigel flagged that Veppanu's launch depends on successful transfer work, strong physician adoption, real patient demand, favorable reimbursement, appropriate pricing, limited competition, positive regulatory outcomes, and tolerable side effects. If any of these factors fall short, or if Pfizer's pipeline trials disappoint, the stock could rely more on cost cuts and the dividend rather than growth.
